Bibliography
- Twelfth Programme Report of the UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR). World Health Organization, Ge-neva (1995).
- NEVILL CG, SOME ES, MUNGALA VO et al: Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop. Med. Int. Health (1996) 1:139–146.
- WINSTANLEY PA: Mefloquine: the benefits outweigh the risks. Br. J Clin. Pharmacol. (1996) 42:411–414.
- NOSTEN F, TER KUILE F, LUXEMBURGER C et al: Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 341:1054–1056.
- SHANKS GD, ROESSLER P: Doxycycline for malaria pro-phylaxis in Australian soldiers deployed to United Na-tions missions in Somalia and Cambodia. Mihaly Med. (1995) 160:443–445.
- BITONTI AJ, SJOERDSMA A, MCCANN PD et al: Reversal of chloroquine resistance in the malaria parasite Plas-modium falciparum by desipramine. Science (1988) 242:1301–1303.
- OLLIARO P, NEVILL C, LEBRAS J etal.: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 348:1196–1201.
- HAWLEY SR, BRAY PG, O'NEILL PM et al.: Manipulation of the n-alkyl substituent of amodiaquine to overcome the verapamil-sensitive chloroquine-resistance compo-nent. Antimicrob. Agents Chemother. (1996) 40:2345–2349.
- HYDE JE: The dihydrofolate-thymidylate synthetase gene in the drug-resistance of malaria parasites. Phar-macol. Ther. (1990) 48:45–59.
- BROOKS DR, WANG P, READ M et al.: Sequence variation of the hydroxymethyldihydropterin pyrophosphoki-nase: dihydropteroate synthetase gene in lines of the human malaria parasite Plasmodium falciparum, with differing resistance to sulfadoxine. Ear. j Biochem. (1994) 224:397–405.
- WATKINS WM, MOSOBO M: Treatment of Plasmodium falciparum malaria with pyrimethamine and sul-phadoxine: a selective pressure for resistance in a function of long elimination half-life. Trans. Roy. Soc. Trop. Med. Hyg (1993) 87:75–79.
- WINSTANLEY PA, MBERU EK, SZWANDT ISF, BRECKEN-RIDGE AM, WATKINS WM: The in vitro activity of novel antifolate drug combinations against Plasmodium fal-ciparum and human granulocyte colony-forming-units. Antimicrob. Agents Chemother. (1995) 39:948–952.
- AMUKOYE E, WINSTANLEY PA, WATKINS WM et al: Chlo-roproguanil/dapsone: an effective treatment for un-complicated falciparum malaria. (In Preparation.)
- CANFIELD CJ, MILHOUS WK, AGER AL et al.: PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop. Med. Hyg. (1993) 49:121–126.
- WHITE NJ: Artemisinin. Trans. Roy. Soc. Trop. Med. Hyg. (1994) 88\(Suppl. 1).
- MURPHY S, WATKINS WM, BRAY P etal: Parasite viability during the treatment of severe falciparum malaria: differential effects of artemether and quinine. Am. J. Trop. Med. Hyg (1995) 53:303–305.
- MURPHY S, ENGLISH M, WARUIRU C et al.: An open randomised trial of artemether versus quinine in the treatment of cerebral malaria in African children. Trans. Roy Soc. Trop. Med. Hyg. (1996) 90:298–301.
- VAN HENSBROEK MB, ONYIORAH E, JAFFAR S etal: Atrialof artemether or quinine in children with cerebral malaria. New Engl. J. Med. (1996) 335:69–75.
- HIEN T, DAY N, PHU N et al.: A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum-malaria. New Engl. J Med. (1996) 335:76–83.
- WINSTANLEY PA: Pyronaridine - a promising drug for Africa? Lancet (1996) 347:2–3.
- RADLOFF PD, PHILLIPS J, NKEYI M, HUTCHINSON D,KREMSNER PG: Atovaquone and proguanil for Plasmo-dium falciparum malaria. Lancet (1996) 347:1511–1514.